Terry Shaunessy BMO NASDAQ 100 HEDGED TO CAD INDEX ETF ZQQ-T DON'T BUY Dec 09, 2020

He'd be more cautious of HTA, because if he's going to take the risk of tech, he wants to have the full growth potential of that and not be somewhat coralled by covered calls. On tech, he'd be doing ZQQ.

Prominent names. Be careful of the valuations of NASDAQ, as the average PE is 38x on this ETF, average price to sales is 4.3x. Makes sense as part of a portfolio, but watch the valuation.

62% tech, with the rest being in consumer discretionary, healthcare, etc. Trading about 30x PE, 4.7x price to sales, which is above the 10-year average of 26x PE and 3.8x price to sales. Elevated valuation. He'd prefer the general NASDAQ index over just the tech index. Cost is 39 bps, a portion in your portfolio could make sense.

AI is going to be as transformative as the internet. The Magnificent 7 are for real and must be owned, though some are more pricey. When you buy this basket, you get a nice mix and it's just easier. Likes that it's hedged, so you can invest as if you were an American. Likes the tech along with the healthcare names.

A lot of the tech stocks are approaching their price targets, so what's an investor to do? He always recommends writing some calls, actively managing them. You can do this on ETFs over the counter.

Runway for SOXX is probably longer than that of the ZQQ.

Will continue to own shares. Good option for investors to include in portfolio. 

Likes it and uses it often. It's fine as a core holding. AI offers huge growth ahead.

Remember that some of the semis are very cyclical. Right now, there's an oversupply on the memory side, which you can see with the likes of ASML. And you can see this ETF rolling over. He stays away from ETFs because they're a mixed bag. The place you want to be in semis is in AI chips -- like NVDA, and AVGO (nipping at NVDA's heels).

Mag 7 and lots of it, so it will have some volatility. But he still likes it.

Names are the usual tech suspects. For him, he'd rather pick and choose names for his portfolio, as some names are very expensive and some are very reasonable. MER is 39 bps, and you can probably find cheaper ones in the US. Down 14% from highs, but still up 6.6% in a 1-year timeframe. 

Might make sense for an investor who wants a broader approach and not as much Pepto Bismol ;)